院長紹介
ご挨拶
気軽に相談できる
クリニックを目指して
開院以来、地域の医療関係者の皆さんと連携しながら、患者さんやご家族の健康のサポートを行っています。特に、認知症や精神疾患などの専門分野について、かかりつけ医の先生や、ケアマネージャーさん、関連施設と連携して患者さんやご家族を支援するよう心掛けています。また、地域のかかりつけ医として内科・認知症・精神科もあわせて診療していますので、気軽にご相談ください。病状に応じて、他の医療機関や施設へもしっかりと紹介いたします。
認知症や精神疾患をもつ患者さんのご家族は、悩みを抱え込んで疲れてしまうことが非常に多いく、なるべくご家族の不安や孤独を減らしたいという思いがあります。診察時でも、お手紙でも構いません。お困りの方は気軽にご相談ください。
院長 松永 慎史
相生山ほのぼのメモリークリニックの松永慎史です。
少子高齢化が進み、からだの病気だけでなく、認知症やこころの病も増えています。そのため、当クリニックは皆様の「認知症」、「からだ」、「こころ」の悩みを総合的に相談できるクリニックを目標に開院いたします。
当クリニックでは、医師だけでなく、看護師、心理士、精神保健福祉士、医療事務と多職種で、患者さんとそのご家族をサポートしてまいります。
病院というのは、かかりづらい所ですが、地域の皆様に気軽に悩みをご相談いただけるような、”ほのぼの”とした雰囲気のクリニックを目指してまいります。
どうぞ、よろしくお願いたします。
略歴・経歴
- 2007年藤田医科大学医学部 卒業
- 2007年藤田医科大学病院 研修医
- 2009年藤田医科大学医学部 精神神経科
- 2011年医療法人静心会 桶狭間病院 藤田こころケアセンター 医長
- 2014年藤田医科大学医学部 精神神経科講師
- 2018年藤田医科大学医学部 認知症・高齢診療科(内科) 講師
- 2020年相生山ほのぼのメモリークリニック開院
資格
- 日本認知症学会 専門医・指導医
- 日本老年精神医学会 専門医・指導医
- 日本精神神経学会 専門医・指導医
- 日本精神神経学会 認知症診療医
- 精神保健指定医
- 難病指定医
- レビー小体型認知症研究会 推奨医
- 認知症サポート医
書籍
家族のためのはじめての認知症ガイド
家族が認知症かも？と思ったとき、まず手に取りたい1冊。病院の選び方・相談先、認知症の種類・症状、本人へのかかわり方、介護保険サービスの種類・使い方、活用できる制度など、フルカラーで整理しました。 「本人が受診を嫌がる…」「どこに相談すればいい？」「どの病院・医師を選べばいい？」「治療費が高くて不安…」 そんな家族のお悩みを、認知症専門医がやさしく解決へと導きます。論文
-
1: Long-term follow-up of insulin autoimmune syndrome in an
elderly patient.
Yoshino H, Kawakami K, Kohriyama K, Yoshino G, Matsunaga S, Takechi H.
Clin Case Rep. 2020 Sep 14;8(12):2941-2944. doi: 10.1002/ccr3.3150. PMID: 33363855; PMCID: PMC7752643. -
2: Relationship between subjective memory complaints and
social and leisure
activities in community-dwelling older people: Toyoake Integrated Care Study.
Takechi H, Tsuzuki A, Matsumoto K, Matsunaga S, Nishiyama H, Ogawa M, Kanada
Y.
Geriatr Gerontol Int. 2020 Oct;20(10):867-872. doi: 10.1111/ggi.13992. Epub 2020 Jul 29. PMID: 32725916. -
3: Increase in direct social care costs of Alzheimer’s
disease in Japan depending on
dementia severity.
Takechi H, Kokuryu A, Kuzuya A, Matsunaga S.
Geriatr Gerontol Int. 2019 Oct;19(10):1023-1029. doi: 10.1111/ggi.13764. Epub 2019 Sep 2. PMID: 31478311. -
4: Efficacy and Safety of Cholinesterase Inhibitors for
Mild Cognitive Impairment: A
Systematic Review and Meta-Analysis.
Matsunaga S, Fujishiro H, Takechi H.
J Alzheimers Dis. 2019 Aug 12;71(2):513-523. doi: 10.3233/JAD-190546. PMID: 31424411. -
5: Efficacy and Safety of Glycogen Synthase Kinase 3
Inhibitors for Alzheimer’s
Disease: A Systematic Review and Meta-Analysis.
Matsunaga S, Fujishiro H, Takechi H.
J Alzheimers Dis. 2019;69(4):1031-1039. doi: 10.3233/JAD-190256. PMID: 31156177. -
6: Influx of Tau and Amyloid-β Proteins into the Blood
During Hemodialysis as a
Therapeutic Extracorporeal Blood Amyloid-β Removal System for Alzheimer’s
Disease.
Kitaguchi N, Tatebe H, Sakai K, Kawaguchi K, Matsunaga S, Kitajima T, Tomizawa H, Kato M, Sugiyama S, Suzuki N, Mizuno M, Takechi H, Nakai S, Hiki Y, Kushimoto H, Hasegawa M, Yuzawa Y, Tokuda T.
J Alzheimers Dis. 2019;69(3):687-707. doi: 10.3233/JAD-190087. PMID: 31156161. -
7: Efficacy and safety of idalopirdine for Alzheimer’s
disease: a systematic review
and meta-analysis.
Matsunaga S, Fujishiro H, Takechi H.
Int Psychogeriatr. 2019 Nov;31(11):1627-1633. doi: 10.1017/S1041610218002156. Epub 2018 Dec 18. PMID: 30560763. -
8: Suvorexant for insomnia in patients with psychiatric
disorder: A 1-week,
open-label study.
Kishi T, Sakuma K, Okuya M, Ninomiya K, Oya K, Kubo M, Matsui Y, Nomura I, Okuyama Y, Matsunaga S, Iwata N.
Neuropsychopharmacol Rep. 2019 Sep;39(3):252-255. doi: 10.1002/npr2.12069. Epub 2019 Jul 8. PMID: 31283862; PMCID: PMC7292311. -
9: Removal of blood amyloid-β with hemodialysis reduced
brain amyloid-β, confirmed
by brain imaging: a case report.
Kitaguchi N, Kato T, Matsunaga S, Hirano K, Iwata K, Kawaguchi K, Fujita K, Takechi H, Hasegawa M, Yuzawa Y, Ito K.
Neuropsychiatr Dis Treat. 2018 Nov 1;14:2931-2937. doi: 10.2147/NDT.S186118. PMID: 30464477; PMCID: PMC6219271. -
10: Memantine treatment for Japanese patients with moderate
to severe Alzheimer’s
disease: a meta-analysis of double-blind, randomized, placebo-controlled trials.
Kishi T, Matsunaga S, Iwata N.
Neuropsychiatr Dis Treat. 2018 Oct 30;14:2915-2922. doi: 10.2147/NDT.S187320. PMID: 30464475; PMCID: PMC6214597. -
11: Efficacy, Acceptability, and Safety of Intravenous
Immunoglobulin Administration
for Mild-To-Moderate Alzheimer’s Disease: A Systematic Review and
Meta-Analysis.
Okuya M, Matsunaga S, Ikuta T, Kishi T, Iwata N.
J Alzheimers Dis. 2018;66(4):1379-1387. doi: 10.3233/JAD-180888. PMID: 30452419. -
12: The efficacy and safety of memantine for the treatment
of Alzheimer’s
disease.
Matsunaga S, Kishi T, Nomura I, Sakuma K, Okuya M, Ikuta T, Iwata N.
Expert Opin Drug Saf. 2018 Oct;17(10):1053-1061. doi: 10.1080/14740338.2018.1524870. Epub 2018 Sep 26. PMID: 30222469. -
13: Folic acid/methylfolate for the treatment of
psychopathology in schizophrenia: a
systematic review and meta-analysis.
Sakuma K, Matsunaga S, Nomura I, Okuya M, Kishi T, Iwata N.
Psychopharmacology (Berl). 2018 Aug;235(8):2303-2314. doi: 10.1007/s00213-018-4926-4. Epub 2018 May 22. PMID: 29785555. -
14: Anti-Dementia Drugs for Psychopathology and Cognitive
Impairment in
Schizophrenia: A Systematic Review and Meta-Analysis.
Kishi T, Ikuta T, Oya K, Matsunaga S, Matsuda Y, Iwata N.
Int J Neuropsychopharmacol. 2018 Aug 1;21(8):748-757. doi: 10.1093/ijnp/pyy045. PMID: 29762677; PMCID: PMC6070030. -
15: Memantine for Alzheimer’s Disease: An Updated
Systematic Review and
Meta-analysis.
Kishi T, Matsunaga S, Oya K, Nomura I, Ikuta T, Iwata N.
J Alzheimers Dis. 2017;60(2):401-425. doi: 10.3233/JAD-170424. PMID: 28922160. -
16: The effects of memantine on behavioral disturbances in
patients with Alzheimer’s
disease: a meta-analysis.
Kishi T, Matsunaga S, Iwata N.
Neuropsychiatr Dis Treat. 2017 Jul 20;13:1909-1928. doi: 10.2147/NDT.S142839. PMID: 28790827; PMCID: PMC5530072. -
17: Comparative efficacy and safety of antipsychotics in
the treatment of
schizophrenia: a network meta-analysis in a Japanese population.
Kishi T, Ikuta T, Matsunaga S, Matsuda Y, Oya K, Iwata N.
Neuropsychiatr Dis Treat. 2017 May 11;13:1281-1302. doi: 10.2147/NDT.S134340. PMID: 28553116; PMCID: PMC5439983. -
18: A Meta-Analysis of Memantine for Depression.
Kishi T, Matsunaga S, Iwata N.
J Alzheimers Dis. 2017;57(1):113-121. doi: 10.3233/JAD-161251. PMID: 28222534. -
19: Combination Therapy with Zonisamide and Antiparkinson
Drugs for Parkinson’s
Disease: A Meta-Analysis.
Matsunaga S, Kishi T, Iwata N.
J Alzheimers Dis. 2017;56(4):1229-1239. doi: 10.3233/JAD-161068. PMID: 28157097. -
20: Escitalopram versus paroxetine controlled release in
major depressive disorder:
a randomized trial.
Kishi T, Matsuda Y, Matsunaga S, Moriwaki M, Otake Y, Akamatsu K, Okochi T, Hirano S, Funahashi T, Okuda M, Tabuse H, Fujita K, Iwata N.
Neuropsychiatr Dis Treat. 2017 Jan 6;13:117-125. doi: 10.2147/NDT.S124898. PMID: 28123299; PMCID: PMC5230634. -
21: Efficacy and tolerability of topiramate-augmentation
therapy for schizophrenia:
a systematic review and meta-analysis of randomized controlled trials.
Okuyama Y, Oya K, Matsunaga S, Kishi T, Iwata N.
Neuropsychiatr Dis Treat. 2016 Dec 15;12:3221-3236. doi: 10.2147/NDT.S125367. PMID: 28008259; PMCID: PMC5170618. -
22: A randomized trial of aripiprazole vs blonanserin for
the treatment of acute
schizophrenia and related disorders.
Kishi T, Matsuda Y, Matsunaga S, Mukai T, Moriwaki M, Tabuse H, Fujita K, Iwata N.
Neuropsychiatr Dis Treat. 2016 Nov 28;12:3041-3049. doi: 10.2147/NDT.S121588. PMID: 27932884; PMCID: PMC5135406. -
23: Tsoi KK et al: Combination Therapy Showed Limited
Superiority Over Monotherapy
for Alzheimer Disease: A Meta-analysis of 14 Randomized Trials.
Matsunaga S, Kishi T, Iwata N.
J Am Med Dir Assoc. 2016 Nov 1;17(11):1061-1062. doi: 10.1016/j.jamda.2016.07.020. Epub 2016 Aug 31. PMID: 27590403. -
24: Yokukansan in the Treatment of Behavioral and
Psychological Symptoms of
Dementia: An Updated Meta-Analysis of Randomized Controlled Trials.
Matsunaga S, Kishi T, Iwata N.
J Alzheimers Dis. 2016 Sep 6;54(2):635-43. doi: 10.3233/JAD-160418. PMID: 27497482. -
25: Efficacy and tolerability of Z-drug adjunction to
antidepressant treatment for
major depressive disorder: a systematic review and meta-analysis of randomized
controlled trials.
Kishi T, Matsunaga S, Iwata N.
Eur Arch Psychiatry Clin Neurosci. 2017 Mar;267(2):149-161. doi: 10.1007/s00406-016-0706-5. Epub 2016 Jun 18. PMID: 27318835. -
26: An autopsy case of cortical superficial siderosis with
persistent abnormal
behavior.
Torii Y, Iritani S, Fujishiro H, Sekiguchi H, Habuchi C, Umeda K, Matsunaga S, Mimuro M, Ozaki N, Yoshida M, Fujita K.
Neuropathology. 2016 Dec;36(6):544-550. doi: 10.1111/neup.12301. Epub 2016 Apr 18. PMID: 27090856. -
27: Mortality Risk Associated With Long-acting Injectable
Antipsychotics: A
Systematic Review and Meta-analyses of Randomized Controlled Trials.
Kishi T, Matsunaga S, Iwata N.
Schizophr Bull. 2016 Nov;42(6):1438-1445. doi: 10.1093/schbul/sbw043. Epub 2016 Apr 16. PMID: 27086079; PMCID: PMC5049525. -
28: Azapirones for Attention Deficit Hyperactivity
Disorder: A Systematic
Review.
Matsui Y, Matsunaga S, Matsuda Y, Kishi T, Iwata N.
Pharmacopsychiatry. 2016 May;49(3):97-106. doi: 10.1055/s-0042-102457. Epub 2016 Apr 13. PMID: 27074948. -
29: N. Serotonin 2A Receptor Inverse Agonist as a Treatment
for Parkinson’s Disease
Psychosis: A Systematic Review and Meta-analysis of Serotonin 2A Receptor Negative
Modulators.
Yasue I, Matsunaga S, Kishi T, Fujita K, Iwata.
J Alzheimers Dis. 2016;50(3):733-40. doi: 10.3233/JAD-150818. PMID: 26757194. -
30: Memantine for the treatment of frontotemporal dementia:
a meta-analysis.
Kishi T, Matsunaga S, Iwata N.
Neuropsychiatr Dis Treat. 2015 Nov 12;11:2883-5. doi: 10.2147/NDT.S94430. PMID: 26648724; PMCID: PMC4648602. -
31: Histamine H3 Receptor Antagonists for Alzheimer’s
Disease: A Systematic Review
and Meta-Analysis of Randomized Placebo-Controlled Trials.
Kubo M, Kishi T, Matsunaga S, Iwata N.
J Alzheimers Dis. 2015;48(3):667-71. doi: 10.3233/JAD-150393. PMID: 26402104. -
32: Lithium as a Treatment for Alzheimer’s Disease: A
Systematic Review and
Meta-Analysis.
Matsunaga S, Kishi T, Annas P, Basun H, Hampel H, Iwata N.
J Alzheimers Dis. 2015;48(2):403-10. doi: 10.3233/JAD-150437. PMID: 26402004. -
33: Antipsychotic medications for the treatment of
delirium: a systematic review and
meta-analysis of randomized controlled trials.
Kishi T, Hirota T, Matsunaga S, Iwata N.
J Neurol Neurosurg Psychiatry. 2016 Jul;87(7):767-74. doi: 10.1136/jnnp-2015-311049. Epub 2015 Sep 4. PMID: 26341326. -
34: Suvorexant for Primary Insomnia: A Systematic Review
and Meta-Analysis of
Randomized Placebo-Controlled Trials.
Kishi T, Matsunaga S, Iwata N.
PLoS One. 2015 Aug 28;10(8):e0136910. doi: 10.1371/journal.pone.0136910. PMID: 26317363; PMCID: PMC4552781. -
35: Efficacy and safety of oxytocin augmentation therapy
for schizophrenia: an
updated systematic review and meta-analysis of randomized, placebo-controlled
trials.
Oya K, Matsuda Y, Matsunaga S, Kishi T, Iwata N.
Eur Arch Psychiatry Clin Neurosci. 2016 Aug;266(5):439-50. doi: 10.1007/s00406-015-0634-9. Epub 2015 Aug 25. PMID: 26303414. -
36: Intramuscular olanzapine for agitated patients: A
systematic review and
meta-analysis of randomized controlled trials.
Kishi T, Matsunaga S, Iwata N.
J Psychiatr Res. 2015 Sep;68:198-209. doi: 10.1016/j.jpsychires.2015.07.005. Epub 2015 Jul 6. PMID: 26228420. -
37: Cholinesterase Inhibitors for Lewy Body Disorders: A
Meta-Analysis.
Matsunaga S, Kishi T, Yasue I, Iwata N.
Int J Neuropsychopharmacol. 2015 Jul 28;19(2):pyv086. doi: 10.1093/ijnp/pyv086. Erratum in: Int J Neuropsychopharmacol. 2016 Apr 27;19(10):pyw031. doi: 10.1093/ijnp/pyw031. PMID: 26221005; PMCID: PMC4772820. -
38: Protection against Brain Atrophy by Anti-dementia
Medication in Mild Cognitive
Impairment and Alzheimer’s Disease: Meta-Analysis of Longitudinal Randomized
Placebo-Controlled Trials.
Kishi T, Matsunaga S, Oya K, Ikuta T, Iwata N.
Int J Neuropsychopharmacol. 2015 Jun 19;18(12):pyv070. doi: 10.1093/ijnp/pyv070. PMID: 26091818; PMCID: PMC4675981. -
39: Hypochondriasis as an early manifestation of dementia
with Lewy bodies: an
autopsied case report.
Fujishiro H, Iritani S, Sekiguchi H, Habuchi C, Torii Y, Matsunaga S, Ozaki N, Yoshida M, Fujita K.
Psychogeriatrics. 2016 Mar;16(2):139-44. doi: 10.1111/psyg.12128. Epub 2015 Apr 27. PMID: 25919332. -
40: Memantine monotherapy for Alzheimer’s disease: a
systematic review and
meta-analysis.
Matsunaga S, Kishi T, Iwata N.
PLoS One. 2015 Apr 10;10(4):e0123289. doi: 10.1371/journal.pone.0123289. PMID: 25860130; PMCID: PMC4393306. -
41: Autopsy-confirmed hippocampal-sparing Alzheimer’s
disease with delusional
jealousy as initial manifestation.
Fujishiro H, Iritani S, Hattori M, Sekiguchi H, Matsunaga S, Habuchi C, Torii Y, Umeda K, Ozaki N, Yoshida M, Fujita K.
Psychogeriatrics. 2015 Sep;15(3):198-203. doi: 10.1111/psyg.12105. Epub 2015 Mar 3. PMID: 25737011. -
42: Aripiprazole for the management of schizophrenia in the
Japanese population: a
systematic review and meta-analysis of randomized controlled trials.
Kishi T, Matsuda Y, Matsunaga S, Iwata N.
Neuropsychiatr Dis Treat. 2015 Feb 20;11:419-34. doi: 10.2147/NDT.S78977. PMID: 25759585; PMCID: PMC4345995. -
43: A cross-sectional survey to investigate the prevalence
of pain in Japanese
patients with major depressive disorder and schizophrenia.
Kishi T, Matsuda Y, Mukai T, Matsunaga S, Yasue I, Fujita K, Okochi T, Hirano S, Kajio Y, Funahashi T, Akamatsu K, Ino K, Okuda M, Tabuse H, Iwata N.
Compr Psychiatry. 2015 May;59:91-7. doi: 10.1016/j.comppsych.2015.02.004. Epub 2015 Feb 17. PMID: 25724075. -
44: Combination therapy with cholinesterase inhibitors and
memantine for Alzheimer’s
disease: a systematic review and meta-analysis.
Matsunaga S, Kishi T, Iwata N.
Int J Neuropsychopharmacol. 2014 Dec 28;18(5):pyu115. doi: 10.1093/ijnp/pyu115. PMID: 25548104; PMCID: PMC4376554. -
45: Iminodibenzyl class antipsychotics for schizophrenia: a
systematic review and
meta-analysis of carpipramine, clocapramine, and mosapramine.
Kishi T, Matsunaga S, Matsuda Y, Iwata N.
Neuropsychiatr Dis Treat. 2014 Dec 10;10:2339-51. doi: 10.2147/NDT.S73464. PMID: 25525363; PMCID: PMC4266422. -
46: Memantine for Lewy body disorders: systematic review
and meta-analysis.
Matsunaga S, Kishi T, Iwata N.
Am J Geriatr Psychiatry. 2015 Apr;23(4):373-383. doi: 10.1016/j.jagp.2013.11.007. Epub 2013 Dec 4. PMID: 24406251. -
47: An evaluation of polymorphisms in casein kinase 1 delta
and epsilon genes in
major psychiatric disorders.
Matsunaga S, Ikeda M, Kishi T, Fukuo Y, Aleksic B, Yoshimura R, Okochi T, Yamanouchi Y, Kinoshita Y, Kawashima K, Umene-Nakano W, Inada T, Kunugi H, Kato
T, Yoshikawa T, Ujike H, Nakamura J, Ozaki N, Kitajima T, Iwata N.
Neurosci Lett. 2012 Oct 31;529(1):66-9. doi: 10.1016/j.neulet.2012.08.070. Epub 2012 Sep 7. PMID: 22981886. -
48: The serotonin 1A receptor gene confer susceptibility to
mood disorders: results
from an extended meta-analysis of patients with major depression and bipolar
disorder.
Kishi T, Yoshimura R, Fukuo Y, Okochi T, Matsunaga S, Umene-Nakano W, Nakamura J, Serretti A, Correll CU, Kane JM, Iwata N.
Eur Arch Psychiatry Clin Neurosci. 2013 Mar;263(2):105-18. doi: 10.1007/s00406-012-0337-4. Epub 2012 Jul 3. PMID: 22752684. -
49: The CLOCK gene and mood disorders: a case-control study
and meta-analysis.
Kishi T, Yoshimura R, Fukuo Y, Kitajima T, Okochi T, Matsunaga S, Inada T, Kunugi H, Kato T, Yoshikawa T, Ujike H, Umene-Nakano W, Nakamura J, Ozaki N, Serretti A, Correll CU, Iwata N.
Chronobiol Int. 2011 Nov;28(9):825-33. doi: 10.3109/07420528.2011.609951. PMID: 22080789. -
50: Possible association between ubiquitin-specific
peptidase 46 gene and major
depressive disorders in the Japanese population.
Fukuo Y, Kishi T, Kushima I, Yoshimura R, Okochi T, Kitajima T, Matsunaga S, Kawashima K, Umene-Nakano W, Naitoh H, Inada T, Nakamura J, Ozaki N, Iwata N.
J Affect Disord. 2011 Sep;133(1-2):150-7. doi: 10.1016/j.jad.2011.04.020. Epub 2011 Jun 12. PMID: 21663972.
ご予約はこちら
Reservation
初診WEB予約はこちら
※再診はお電話にてご予約ください
052-896-0088
- 診療時間
- 9:00〜13:00 / 16:00〜19:00
- 休診日
- 水曜午後・土曜午後・日曜・祝日
